Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

This study has been completed.

Sponsor:

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Information provided by (Responsible Party):

Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston

ClinicalTrials.gov Identifier:

NCT00684060

First received: May 22, 2008

Last updated: July 7, 2015

Last verified: July 2015

History of Changes

Results First Received: April 9, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Left Ventricular Dysfunction
Interventions:	Biological: Adult stem cells Biological: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment took place at five Network centers and their associated satellite facilities between July 8, 2008 and February 28, 2011. The main centers are located in Ohio, Texas, Florida, Minnesota, and Tennessee. Study brochures, patient informational DVDs, and clinical trials.gov were among the tools used for recruitment.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Stem Cell Arm	Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm	Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Participant Flow: Overall Study

	Stem Cell Arm	Placebo Arm
STARTED	58	29
COMPLETED	55	26
NOT COMPLETED	3	3
Lost to Follow-up	1	0
New stenosis identified	1	0
Unable to collect MRI	1	2
Death	0	1

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Stem Cell Arm	Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm	Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
Total	Total of all reporting groups

Baseline Measures

	Stem Cell Arm	Placebo Arm	Total
Overall Participants Analyzed [Units: Participants]	58	29	87

Age [Units: Years] Mean (Standard Deviation)	57.6 (11)	54.6 (11)	57 (11)

Gender [Units: Participants]
Female	12	3	15
Male	46	26	72

Region of Enrollment [Units: Participants]
United States	58	29	87

Outcome Measures

Show All Outcome Measures

1. Primary:

Global Left Ventricular Function [ Time Frame: Measured at Baseline and Month 6 ]

Hide Outcome Measure 1

Measure Type	Primary
Measure Title	Global Left Ventricular Function
Measure Description	Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.
Time Frame	Measured at Baseline and Month 6

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Only participants with both baseline and 6 month MRI images available are included. Values reported represent the change in Global EF from baseline to six months.

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Only participants with both baseline and 6 month MRI images available are included.

Values reported represent the change in Global EF from baseline to six months.

Reporting Groups

	Description
Stem Cell Arm	Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm	Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Measured Values

	Stem Cell Arm	Placebo Arm
Participants Analyzed [Units: Participants]	55	26
Global Left Ventricular Function [Units: Percentage of ejection fraction] Mean (Standard Deviation)	0.5 (8.2)	3.6 (9.3)

Statistical Analysis 1 for Global Left Ventricular Function

Groups ^[1]	All groups
Statistical Test Type ^[2]	Superiority or Other
Statistical Method ^[3]	t-test, 2 sided
P Value ^[4]	<0.05
Mean Difference (Net) ^[5]	-3.0
95% Confidence Interval	-7.05 to .95
Standard Error of the mean	(8.6)

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	Comparison of change in global LVEF in the active group minus change in global LVEF in the control group. 80 percent power based on BOOST results
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	No text entered.
[3]	Other relevant method information, such as adjustments or degrees of freedom:
	No adjustment for multiple comparisons
[4]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	Threshold 0.05
[5]	Other relevant estimation information:
	No text entered.

2. Primary:

Regional Left Ventricular Function (Infarct Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 2

3. Primary:

Regional Left Ventricular Function (Border Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 3

4. Secondary:

Combined Endpoint [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 4

5. Secondary:

Left Ventricular Mass [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 5

6. Secondary:

End Diastolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ]

Hide Outcome Measure 6

Measure Type	Secondary
Measure Title	End Diastolic Volume Index
Measure Description	Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.
Time Frame	Measured at Baseline and Month 6

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Only participants with both baseline and 6 month MRI images available are included. Values reported represent the change in LV end diastolic index from baseline to six months.

Only participants with both baseline and 6 month MRI images available are included.

Values reported represent the change in LV end diastolic index from baseline to six months.

Reporting Groups

	Description
Stem Cell Arm	Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
Placebo Arm	Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.

Measured Values

	Stem Cell Arm	Placebo Arm
Participants Analyzed [Units: Participants]	55	26
End Diastolic Volume Index [Units: mL/m2] Mean (Standard Deviation)	3.4 (23.4)	2.7 (18.1)

Statistical Analysis 1 for End Diastolic Volume Index

Groups ^[1]	All groups
Statistical Test Type ^[2]	Superiority or Other
Statistical Method ^[3]	t-test, 2 sided
P Value ^[4]	<0.05
Mean Difference (Net) ^[5]	0.7
95% Confidence Interval	-9.5 to 10.9
Standard Error of the mean	(21.8)

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	Comparison of change in the active group minus change in global LVEF in the control group.
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	No text entered.
[3]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[4]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.
[5]	Other relevant estimation information:
	No text entered.

7. Secondary:

End Systolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 7

8. Secondary:

Infarct Volume [ Time Frame: Measured at Baseline and Month 6 ]

Show Outcome Measure 8

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Lack of in-vivo testing of cell product. While there are several different approaches to measure myocardial strain (myocardial tagging, DENSE, etc.), these were not employed in this study due to the need for specialized expertise at each site.

More Information

Show More Information

To Top